On the upside
GenVec (Nasdaq: GNVC) reported that its advanced esophageal cancer treatment TNFerade increased median survival time when used in combination with chemoradiation.
Poniard Pharmaceuticals (Nasdaq: PARD) will release more data on Monday from a Phase 2 clinical trial of its colorectal cancer treatment picoplatin.
The Food and Drug Administration approved Acorda Therapeutics' (Nasdaq: ACOR) multiple sclerosis treatment that will help patients walk.
On the downside
Citigroup analyst Timothy Arcuri downgraded Entegris (Nasdaq: ENTG) to a Sell rating.
China Yida Holding (Nasdaq: CNYD) will raise approximately $29 million through a registered direct offering of common stock.
PremierWest Bancorp (Nasdaq: PRWT) widened fourth quarter losses.
In the broad market, declining issues outpaced advancers by a margin of more than 4 to 1 on the NYSE and by more than 5 to 2 on Nasdaq. The Russell 2000 which tracks small cap stocks tumbled 11 points to 617.
